Company / Operating Cash Flow per Share
NovoCure Ltd Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.45
FY2025
5-year range
-$0.70 / $0.95
FY2021-FY2025
Trend
-83.5%
vs FY2024
Sector context
#146 of 161
Health Care
What the data says
Among 161 Health Care companies, NovoCure Ltd is in the bottom 9% for operating cash flow per share. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-1.20 in FY2018 to $0.95 in FY2022.
Based on SEC 10-K filings.
-0.45 in FY2025.
Improved from $-0.70 to $-0.45 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 161This company -$0.45 Sector average $6.64
▼
-106.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 83.5% year-over-year.
- Ranks #146 out of 161 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2022.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.45 | -83.5% |
| FY2024 | -$0.25 | +64.7% |
| FY2023 | -$0.70 | -173.2% |
| FY2022 | $0.95 | +266.6% |
| FY2021 | $0.26 | +1488.2% |
| FY2020 | -$0.02 | +94.7% |
| FY2019 | -$0.36 | +70.5% |
| FY2018 | -$1.20 | -4.8% |
| FY2017 | -$1.15 | -29.5% |
| FY2016 | -$0.89 | +77.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026